Eledon Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Eledon Pharmaceuticals es DA Gros , nombrado en Sep 2020, tiene una permanencia de 4.17 años. compensación anual total es $2.55M, compuesta por 21.9% salario y 78.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.015% de las acciones de la empresa, por valor de $38.26K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 5.9 años, respectivamente.
Información clave
DA Gros
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 21.9% |
| Permanencia del CEO | 4.2yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 5.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Oct 29We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Eledon adds 10% as FDA clears clinical trial for kidney disease candidate
Sep 06Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Eledon gets FDA nod to start trial of organ rejection preventing therapy
Aug 01Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients
Jul 18Eledon gives update on development strategy for AT-1501 in renal transplantation
Apr 26Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans
Apr 14What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?
Feb 21Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation
Dec 30
Novus Therapeutics (NVUS) Investor Presentation - Slideshow
Dec 18Novus Therapeutics EPS misses by $3.76
Nov 16Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease
Nov 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$25m |
| Jun 30 2024 | n/a | n/a | -US$89m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$3m | US$559k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$145m |
| Jun 30 2023 | n/a | n/a | -US$145m |
| Mar 31 2023 | n/a | n/a | -US$89m |
| Dec 31 2022 | US$1m | US$533k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$748k | US$504k | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$7m | US$150k | -US$23m |
Compensación vs. Mercado: La compensación total de DA($USD2.55M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: La compensación de DA ha aumentado mientras la empresa no es rentable.
CEO
DA Gros (52 yo)
4.2yrs
Permanencia
US$2,553,153
Compensación
Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Non Independent Director | 4.2yrs | US$2.55m | 0.015% $ 38.3k | |
| President | 4.2yrs | US$1.54m | 0.0017% $ 4.2k | |
| Chief Financial Officer | 3.7yrs | US$1.32m | 0.017% $ 42.5k | |
| Vice President of Technical Operations | 2.5yrs | sin datos | sin datos | |
| General Counsel | 3.6yrs | US$1.68m | 0% $ 0 | |
| Chief Regulatory Officer | 3.6yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.1yrs | sin datos | sin datos |
3.6yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ELDN se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Non Independent Director | 4.2yrs | US$2.55m | 0.015% $ 38.3k | |
| President | 4.2yrs | US$1.54m | 0.0017% $ 4.2k | |
| Independent Chairman of the Board | 7.5yrs | US$1.52m | 0.0011% $ 2.9k | |
| Independent Director | 7.5yrs | US$371.82k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$201.79k | sin datos | |
| Independent Director | 3.9yrs | US$374.44k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos |
5.9yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de ELDN se considera experimentada (5.9 años de antigüedad promedio).